Evaluation of real-world mobility in age-related macular degeneration

被引：0
|
作者：
Sabyasachi Sengupta
Angeline M Nguyen
Suzanne W van Landingham
Sharon D Solomon
Diana V Do
Luigi Ferrucci
David S Friedman
Pradeep Y Ramulu
机构：
[1] Johns Hopkins University,Wilmer Eye Institute
[2] University of Nebraska Medical Center,Truhlsen Eye Institute
[3] National Institute on Aging,The Longitudinal Studies Section, Clinical Research Branch
[4] National Institutes of Health,Dana Center for Preventive Ophthalmology
[5] Johns Hopkins Bloomberg School of Public Health,undefined
[6] Johns Hopkins University,undefined
来源：
BMC Ophthalmology | / 15卷
关键词：
Age-related macular degeneration; Physical activity; Mobility;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 50 条
  • [21] Real-world evidence in the use of Bevacizumab in age-related macular degeneration (ArMD): a scoping review
    Ainhoa Gomez-Lumbreras
    Priyanka Ghule
    Rupesh Panchal
    Theodoros Giannouchos
    Catherine M. Lockhart
    Diana Brixner
    International Ophthalmology, 2023, 43 : 4527 - 4539
  • [22] Real-world efficacy of intravitreal faricimab for neovascular age-related macular degeneration: a systematic review
    Nasimi, Nasratullah
    Nasimi, Safiullah
    Grauslund, Jakob
    Vergmann, Anna Stage
    Subhi, Yousif
    INTERNATIONAL JOURNAL OF RETINA AND VITREOUS, 2024, 10 (01)
  • [23] METAANALYSIS OF REAL-WORLD OUTCOMES OF INTRAVITREAL RANIBIZUMAB FOR THE TREATMENT OF NEOVASCULAR AGE-RELATED MACULAR DEGENERATION
    Kim, Leah N.
    Mehta, Hemal
    Barthelmes, Daniel
    Vuong Nguyen
    Gillies, Mark C.
    RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES, 2016, 36 (08): : 1418 - 1431
  • [24] Treatment patterns in patients with age-related macular degeneration and diabetic macular edema: A real-world claims analysis in Dubai
    Kozak, Igor
    Gurbaxani, Avinash
    Safar, Ammar
    Rao, Prasan
    Masalmeh, Amal
    Assaf, Hazar
    Farghaly, Mohamed
    Pathak, Prathamesh
    Natarajan, Ashok
    Saffar, Insaf
    PLOS ONE, 2021, 16 (07):
  • [25] Ranibizumab in patients with neovascular age-related macular degeneration: results from the real-world LUMINOUS™ study
    Souied, E.
    Clemens, A.
    Macfadden, W.
    ACTA OPHTHALMOLOGICA, 2017, 95
  • [26] Managing Neovascular Age-Related Macular Degeneration Is More Research Needed to Improve Real-world Practice?
    Virgili, Gianni
    Parravano, Mariacristina
    Schmucker, Christine
    JAMA OPHTHALMOLOGY, 2016, 134 (05) : 553 - 554
  • [27] Real-world evidence for brolucizumab efficacy in age-related macular degeneration and central serous chorioretinopathy patients
    Lacramioara, Samoila
    Ovidiu, Samoila
    Simona, Clichici
    HELIYON, 2024, 10 (10)
  • [28] Initial Real-World Experience with Faricimab in Treatment-Resistant Neovascular Age-Related Macular Degeneration
    Leung, Ella H.
    Oh, Daniel J.
    Alderson, Shannon E.
    Bracy, Joshlynn
    McLeod, Mia
    Perez, Litzi, I
    Bottini, Alexander
    Yee, David Chin
    Mukkamala, Krishna
    CLINICAL OPHTHALMOLOGY, 2023, 17 : 1287 - 1293
  • [29] Early real-world outcomes in patients with neovascular Age-related Macular Degeneration (nAMD) treated with Faricimab
    Raslan, Walid
    Younis, Saad
    Fabozzi, Lorenzo
    Hassan, Islam
    Palmieri, Filomena
    INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE, 2023, 64 (08)
  • [30] Switching to Aflibercept in Ranibizumab Refractory Age-Related Macular Degeneration: a Real-World Experience from Sweden
    Mejaddam, Assem
    Rosso, Aldana
    Westborg, Inger
    INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE, 2017, 58 (08)
12345